Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats

European Respiratory Journal

Volumn 20, Issue 4, 2002, Pages 873-879

  Vanacker, N J ^a   Palmans, E ^a   Pauwels, R A ^a   Kips, J C ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Asthma; Corticosteroids; Dose response; Fluticasone; Rats; Remodelling

Indexed keywords

ALLERGEN; BUFFER; CORTICOSTEROID; CORTICOSTERONE; FIBRONECTIN; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; OVALBUMIN; PHOSPHATE; PLACEBO; PREDNISOLONE HEMISUCCINATE; SODIUM CHLORIDE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL HYPERPLASIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; EOSINOPHIL; EXPOSURE; GOBLET CELL; LUNG LAVAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT MUCOSA; SENSITIZATION;

ADMINISTRATION, INHALATION; AIRWAY RESISTANCE; ANDROSTADIENES; ANIMALS; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; OVALBUMIN; PROBABILITY; RATS; RATS, INBRED BN; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0036798982     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.02562001     Document Type: Article

References (35)

1. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br Med J 2001; 323: 253-256.
2. Chu HW, Halliday JL, Martin RJ, Leung DY, Szefler SJ, Wenzel SE. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med 1998; 158: 1936-1944.
3. Pohunek P, Roche WR, Turzikova J, Kudrmann J, Warner JO. Eosinophilic inflammation in the bronchial mucosa of children with bronchial asthma. Eur Respir J 1997; 10: Suppl. 25, 160s.
4. Boulet LP, Turcotte H, Laviolette M, et al. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162: 1308-1313.
5. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155: 1864-1871.
6. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994; 150: 17-22.
7. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen L. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am J Respir Crit Care Med 1997; 156: 951-958.
8. Hoshino M, Nakamura Y, Sim JJ, et al. Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy 1998; 28: 568-577.
9. Hoshino M, Takahashi M, Takai Y, Sim J. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999; 104: 356-363.
10. Lundgren R, Soderberg M, Horstedt P, Stenling R. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J 1988; 1: 883-889.
11. Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145: 890-899.
12. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159: 1043-1051.
13. Vanacker NJ, Palmans E, Kips JC, Pauwels RA. Fluticasone inhibits but does not reverse allergen induced structural airway changes. Am J Respir Crit Care Med 2001; 163: 674-679.
14. Palmans E, Kips JC, Pauwels RA. Prolonged allergen exposure induces structural airway changes in sensitized rats. Am J Respir Crit Care Med 2000; 161: 627-635.
15. McLean HM, Khalil MA, Heiman AS, Lee HJ. Novel fluorinated antiinflammatory steroid with reduced side effects: methyl 9 alpha-fluoroprednisolone-16-carboxylate. J Pharm Sci 1994; 83: 476-480.
16. Belvisi MG, Wicks SL, Battram CH, et al. Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 2001; 166: 1975-1982.
17. Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999; 54: 108-114.
18. Gershman NH, Wong HH, Liu JT, Fahy JV. Low- and high-dose fluticasone propionate in asthma; effects during and after treatment. Eur Respir J 2000; 15: 11-18.
19. Inman MD, Watson RM, Rerecich T, et al, Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001; 164: 569-574.
20. Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237-243.
21. Denburg JA, Sehmi R, Saito H, Pil-Seob J, Inman MD, O'Byrne PM. Systemic aspects of allergic disease: bone marrow responses. J Allergy Clin Immunol 2000; 106: S242-S246.
22. Inman MD. Bone marrow events in animal models of allergic inflammation and hyperresponsiveness. J Allergy Clin Immunol 2000; 106: S235-S241.
23. Erjefält JS, Erjefält I, Sundler F, Persson CG. Microcirculation-derived factors in airway epithelial repair in vivo. Microvasc Res 1994; 48: 161-178.
24. Meerschaert J, Kelly EA, Mosher DF, Busse WW, Jarjour NN. Segmental antigen challenge increases fibronectin in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 1999; 159: 619-625.
25. Hernnäs J, Nettelbladt O, Bjermer L, Sarnstrand B, Malmstrom A, Hallgren R. Alveolar accumulation of fibronectin and hyaluronan precedes bleomycin-induced pulmonary fibrosis in the rat. Eur Respir J 1992; 5: 404-410.
26. Nocker RE, Weller FR, Out TA, de Riemer MJ, Jansen HM, van der Zee JS. A double-blind study on the effect of inhaled corticosteroids on plasma protein exudation in asthma. Am J Respir Crit Care Med 1999; 159: 1499-1505.
27. Dubaybo BA, Marwah GS, Rubeiz GJ. Steroid responsiveness of fibroblasts of paraquat injured lungs. Res Commun Chem Pathol Pharmacol 1991; 71: 365-380.
28. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32-42.
29. Blyth DI, Pedrick MS, Savage TJ, Bright H, Beesley JE, Sanjar S. Induction, duration, and resolution of airway goblet cell hyperplasia in a murine model of atopic asthma: effect of concurrent infection with respiratory syncytial virus and response to dexamethasone. Am J Respir Cell Mol Biol 1998; 19: 38-54.
30. Blyth DI, Wharton TF, Pedrick MS, Savage TJ, Sanjar S. Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody. Am J Respir Cell Mol Biol 2000; 23: 241-246.
31. Trifilieff A, Fujitani Y, Coyle AJ, Kopf M, Bertrand C. IL-5 deficiency abolishes aspects of airway remodelling in a murine model of lung inflammation. Clin Exp Allergy 2001; 31: 934-942.
32. Cohn L, Homer RJ, MacLead H, Mohrs M, Brombacher F, Bottomly K. Th2-induced airway mucus production is dependent on IL-4R alpha, but not on eosinophils. J Immunol 1999; 162: 6178-6183.
33. Kita H, Jorgensen RK, Reed CE, et al. Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected. J Allergy Clin Immunol 2000; 106: 521-529.
34. Wiggs BR, Bosken C, Pare PD, James A, Hogg JC. A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145: 1251-1258.
35. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476-482.